et al. The antibody aducanumab reduces Aβ plaques in
Alzheimer’s disease. Nature
537, 50–56 (2016)
Mormino, E. &
The evolution of preclinical Alzheimer’s disease: implications
for prevention trials. Neuron
84, 608–622 (2014)
et al. The future of blood-based biomarkers for
Alzheimer’s disease. Alzheimers Dement.
10, 115–131 (2014)
O’Bryant, S. E.
et al. Blood-based biomarkers in Alzheimer disease: Current state of
the science and a novel collaborative paradigm for advancing from discovery
to clinic. Alzheimers Dement.
13, 45–58 (2017)
et al. Changes in plasma amyloid β in a longitudinal
study of aging and Alzheimer’s disease. Alzheimers
10, 53–61 (2014)
et al. Association of plasma and cortical amyloid beta is modulated
by APOE ε4 status. Alzheimers Dement.
10, e9–e18 (2014)
et al. Plasma concentrations of free amyloid β cannot
predict the development of Alzheimer’s disease.
13, 778–782 (2017)
et al. Novel plasma biomarker surrogating cerebral amyloid
deposition. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.
90, 353–364 (2014)
et al. Amyloid β concentrations and stable isotope
labeling kinetics of human plasma specific to central nervous system
amyloidosis. Alzheimers Dement.
13, 841–849 (2017)
et al. Quantitative analysis of amyloid-β peptides in
cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass
spectrometry. Brief. Funct. Genomic. Proteomic.
6, 149–158 (2007)
Kaneko, N., Yamamoto, R., Sato, T. A.
& Tanaka, K.
Identification and quantification of amyloid b-related peptides in human
plasma using matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.
90, 104–117 (2014)
Ellis, K. A.
et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study
of aging: methodology and baseline characteristics of 1112 individuals
recruited for a longitudinal study of Alzheimer’s disease.
21, 672–687 (2009)
et al. 18F-flutemetamol amyloid imaging in Alzheimer
disease and mild cognitive impairment: a phase 2 trial. Ann.
68, 319–329 (2010)
Wong, D. F.
et al. In vivo imaging of amyloid deposition in Alzheimer
disease using the radioligand 18F-AV-45 (florbetapir F
18). J. Nucl. Med.
51, 913–920 (2010)
Landau, S. M.
et al. Amyloid PET imaging in Alzheimer’s disease: a
comparison of three radiotracers. Eur. J. Nucl. Med. Mol.
41, 1398–1407 (2014)
Mormino, E. C.
et al. Amyloid and APOE ε4 interact to influence
short-term decline in preclinical Alzheimer disease.
82, 1760–1767 (2014)
Villemagne, V. L.
et al. En attendant centiloid. Adv. Res.
2, 723–729 (2014)
Fagan, A. M.
et al. Comparison of analytical platforms for cerebrospinal fluid
measures of β-amyloid 1-42, total tau, and p-tau181 for
identifying Alzheimer disease amyloid plaque pathology. Arch.
68, 1137–1144 (2011)
Irwin, D. J.
et al. Comparison of cerebrospinal fluid levels of tau and
Aβ 1-42 in Alzheimer disease and frontotemporal degeneration
using 2 analytical platforms. Arch. Neurol.
69, 1018–1025 (2012)
Jagust, W. J.
et al. Relationships between biomarkers in aging and dementia.
73, 1193–1199 (2009)
Li, Q. X.
et al. Alzheimer’s disease normative cerebrospinal fluid
biomarkers validated in PET amyloid-β characterized subjects
from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
J. Alzheimers Dis.
48, 175–187 (2015)
Shaw, L. M.
et al. Cerebrospinal fluid biomarker signature in
Alzheimer’s disease neuroimaging initiative subjects.
65, 403–413 (2009)
Wang, J., Gu, B. J., Masters, C. L.
& Wang, Y. J.
A systemic view of Alzheimer disease - insights from amyloid-β
metabolism beyond the brain. Nat. Rev. Neurol.
13, 612–623 (2017)
et al. Plasma β-amyloid in Alzheimer’s
disease and vascular disease. Sci. Rep.
6, 26801 (2016)
et al. Plasma amyloid-β levels are significantly
associated with a transition toward Alzheimer’s disease as
measured by cognitive decline and change in neocortical amyloid
burden. J. Alzheimers Dis.
40, 95–104 (2014)
Jarrett, J. T.,
Berger, E. P. &
Lansbury, P. T., Jr.
The C-terminus of the β protein is critical in
amyloidogenesis. Ann. NY Acad. Sci.
695, 144–148 (1993)
Rogers, M. B. Are CSF Assays Finally
Ready for Prime Time? Alzforum
et al. Assessment of the incremental diagnostic value of florbetapir
F 18 imaging in patients with cognitive impairment: the incremental
diagnostic value of amyloid PET with [18F]-florbetapir
(INDIA-FBP) Study. JAMA Neurol.
73, 1417–1424 (2016)
Caselli, R. J. &
Woodruff, B. K.
Clinical impact of amyloid positron emission tomography—is it
worth the cost?
73, 1396–1398 (2016)
O’Bryant, S. E.
et al. Guidelines for the standardization of preanalytic variables
for blood-based biomarker studies in Alzheimer’s disease
research. Alzheimers Dement.
11, 549–560 (2015)
Albert, M. S.
et al. The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: recommendations from the National Institute
on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimers
7, 270–279 (2011)
McKhann, G. M.
et al. The diagnosis of dementia due to Alzheimer’s
disease: recommendations from the National Institute on
Aging–Alzheimer’s Association workgroups on
diagnostic guidelines for Alzheimer’s disease.
7, 263–269 (2011)
Rowe, C. C.
et al. Amyloid imaging results from the Australian Imaging,
Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol.
31, 1275–1283 (2010)
et al. Comparison of MR-less PiB SUVR quantification methods.
36, S159–S166 (2015)
Clark, C. M.
et al. Use of florbetapir-PET for imaging β-amyloid
pathology. J. Am. Med. Assoc.
305, 275–283 (2011)
et al. Implementation and validation of an adaptive template
registration method for 18F-flutemetamol imaging data.
J. Nucl. Med.
54, 1472–1478 (2013)
et al. A selected reaction monitoring (SRM)-based method for
absolute quantification of Aβ38, Aβ40, and
Aβ42 in cerebrospinal fluid of Alzheimer’s disease
patients and healthy controls. J. Alzheimers Dis.
33, 1021–1032 (2013)
Patterson, B. W.
et al. Age and amyloid effects on human central nervous system
amyloid-beta kinetics. Ann. Neurol.
78, 439–453 (2015)
et al. Overcoming synthetic Aβ peptide aging: a new
approach to an age-old problem. Amyloid
16, 71–80 (2009)
et al. N-Terminal pyroglutamate formation of Aβ38 and
Aβ40 enforces oligomer formation and potency to disrupt
hippocampal long-term potentiation. J. Neurochem.
121, 774–784 (2012)
Toombs, J., Paterson, R. W., Schott, J. M. & Zetterberg, H.
Amyloid-beta 42 adsorption following serial tube transfer.
Alzheimers Res. Ther.
6, 5 (2014)
et al. Mass++: A visualization and analysis tool for mass
spectrometry. J. Proteome Res.
13, 3846–3853 (2014)
et al. CSF biomarker variability in the Alzheimer’s
Association quality control program. Alzheimers Dement.
9, 251–261 (2013)
Shapiro, S. S. &
Wilk, M. B.
An analysis of variance test for normality (complete samples).
52, 591–611 (1965)
Youden, W. J.
Index for rating diagnostic tests. Cancer
3, 32–35 (1950)
DeLong, E. R.,
DeLong, D. M. &
Clarke-Pearson, D. L.
Comparing the areas under two or more correlated receiver operating
characteristic curves: a nonparametric approach. Biometrics
44, 837–845 (1988)
D’Agostino, R.B. Sr., D’Agostino, R.B. Jr. & Vasan, R.S.
Evaluating the added predictive ability of a new marker: from area under
the ROC curve to reclassification and beyond. Stat. Med.
27, 157–172 (2008)